Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMWUS8N)

• Drug Name: Licarbazepine Drug Info
• Synonyms: GP 47779; GP-47779; (-)-10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxy-5H-dibenz(b,f)azepine-5-carboxamide; 10,11-Dihydro-10-hydroxycarbamazepine; 10-HYDROXY-CARBAMAZEPINE; 10-Hydroxy-10,11-dihydro-5H-dibenz(b,f)azepine-5-carboxamide; 10-Hydroxy-10,11-dihydrocarbamazepine; 10-Hydroxycarbamazepine; 10-Hydroxycarbazepine; 10-OH-Carbazepine; 5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Bipolar disorder	6A60	Discontinued in Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 114709
  ChEBI ID: CHEBI:701
  CAS Number: CAS 29331-92-8
  TTD Drug ID: DMWUS8N

Molecule-Related Drug Atlas

Drug(s) Targeting Sodium channel unspecific (NaC)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Phenytoin	DMNOKBV	Epilepsy	8A60-8A68	Approved	[3]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[4]
Zonisamide	DM0DTF7	Alcohol dependence	6C40.2	Approved	[5]
Eslicarbazepine	DMZREFQ	Seizure disorder	8A6Z	Approved	[6]
LIDOFLAZINE	DMV23GL	Angina pectoris	BA40	Approved	[7]
LOMERIZINE	DME0TC8	Migraine	8A80	Approved	[8]
Levobupivacaine	DM783CH	Anaesthesia	9A78.6	Approved	[9]
Tetrodotoxin	DMWMPRG	Bacterial infection	1A00-1C4Z	Approved	[10]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[11]
Rufinamide	DMWE60C	Epilepsy	8A60-8A68	Approved	[12]

Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flupentixol	DM0DJ9O	Schizophrenia	6A20	Approved	[13]
Sertraline	DM0FB1J	Coronary heart disease	BA80.Z	Approved	[14]
Crizotinib	DM4F29C	Non-small-cell lung cancer	2C25.Y	Approved	[15]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[16]
Cepharanthine	DM9Y5JB	N. A.	N. A.	Approved	[17]
Itraconazole	DMCR1MV	Aspergillosis	1F20	Approved	[18]
Clozapine	DMFC71L	Schizophrenia	6A20	Approved	[19]
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[20]
Trifluoperazine	DMKBYWI	Anxiety		Approved	[21]
Olanzapine	DMPFN6Y	Bipolar depression		Approved	[19]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Sodium channel unspecific (NaC)	TTRK8B9	NOUNIPROTAC	Blocker	[1]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Regulation of Drug Effects	[2]

References

• [1] Emerging drugs for bipolar disorder. Expert Opin Emerg Drugs. 2006 Nov;11(4):621-34.
• [2] A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5-carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine. Epilepsia. 2005 Oct;46(10):1613-9. doi: 10.1111/j.1528-1167.2005.00265.x.
• [3] Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
• [4] Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
• [5] Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
• [6] Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
• [7] Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
• [8] Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
• [9] Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
• [10] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [11] In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
• [12] Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
• [13] Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
• [14] Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
• [15] Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
• [16] Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
• [17] Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
• [18] Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
• [19] Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
• [20] Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
• [21] Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.